Tag: Chinese medical firm
CSL to buy majority stake in a leading Chinese plasma fractionator
Australian biotech firm CSL has agreed to acquire an 80% stake in China’s plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (Ruide) in...
Featured Article
Responding to manufacturing demand and performance signals
Australian manufacturers are navigating a challenging environment. Just as output had returned to growth, higher fuel and freight costs, rising input prices and global supply chain disruption renewed pressure on margins and cash flow.
